OMEPRAZOLE EXTENDED-RELEASE CAPSULES

The U.S. Department of Defense, through the Defense Logistics Agency, awarded a firm-fixed-price delivery order to DMS PHARMACEUTICAL GROUP INC (CAGE 1UNB0) under the overarching contract SPE2DX25D9900 for the supply of 3,000 bottles of OMEPRAZOLE EXTENDED-RELEASE CAPSULES, identified by NSN 6505016247068 and NDC 00781-2868-92. The total contract value is $152.40, with no quantity variance permitted and delivery required by July 1, 2026. The primary delivery location is Kunsan Air Base, South Korea, with an alternate APO address in the United States, and the shipment is governed by FOB Destination terms, placing full responsibility for transportation, risk, and delivery compliance on the contractor. Packaging and labeling must include the manufacturer’s CAGE code OTHL4 and the specified NSN and NDC, though detailed packaging standards, barcoding requirements, or MIL-STD specifications are not explicitly outlined. Inspection and acceptance occur at the destination, and no specific quality standards such as USP or FDA are cited, though medical substitution ranking RANK 01 is referenced. The award was issued under a NAICS code 424210 for pharmaceutical wholesale, but no socioeconomic certifications, set-aside status, or small business status is indicated. Contract administration details are limited, with no named contracting officer, COR, or COTR provided; payment terms reference a contractor-funded FOB method without specifying invoicing systems like WAWF or IPP. The order constitutes a single, non-option line item under a larger IDIQ vehicle, with no future quantities, pricing options, or extension terms defined.